What do systematic reviews say?

Peritoneoscopic vs open surgical PD catheter insertion

It is very uncertain whether peritoneoscopic changes long‐term PD catheter function (> 4 weeks following PD catheter… compared with open surgical PD catheter insertion (very low certainty).

• Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis patients 2023 · Cochrane Headline outcomes only
  RR 0.59 [0.38, 0.92]
  1 study · 116 participants
  Very low

Fecal microbiota transplantation vs control

Fecal microbiota transplantation may leads to higher induction of clinical remission in UC at longest compared with control (low certainty).

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.79 [1.13, 2.84]
  10 studies · 468 participants
  Low

Fecal microbiota transplantation vs control

Fecal microbiota transplantation showed no clear difference in induction of endoscopic remission in UC at longest compared with control (low certainty).

• Fecal transplantation for treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
  RR 1.45 [0.64, 3.29]
  5 studies · 285 participants
  Low

Culturally and literacy adapted telephone education vs unrelated health literacy intervention

• Interventions for improving health literacy in migrants 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 431 participants
  Moderate

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

It is very uncertain whether tenofovir‐based antiviral combination regimens changes all‐cause infant mortality at longest compared with placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens (very low certainty).

• Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive… 2023 · Cochrane Headline outcomes only
  RR 2.24 [0.72, 6.96]
  1 study · 132 participants
  Very low

Tenofovir‐based antiviral combination regimens vs placebo or tenofovir alone or non‐tenofovir‐based antiviral regimens

• Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Variable flow vs bubble CPAP

The review found no eligible studies for this question.

• Continuous positive airway pressure (CPAP) for apnoea of prematurity 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Infant Flow CPAP vs continuous positive airway pressure (CPAP)

The review found no eligible studies for this question.

• Continuous positive airway pressure (CPAP) for apnoea of prematurity 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Continuous positive airway pressure (CPAP) plus best supportive care vs supportive care

The review found no eligible studies for this question.

• Continuous positive airway pressure (CPAP) for apnoea of prematurity 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Variable flow vs ventilator CPAP

The review found no eligible studies for this question.

• Continuous positive airway pressure (CPAP) for apnoea of prematurity 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher long‐term hair regrowth ≥ 75% (greater than 26 weeks of compared with placebo (high certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 8.49 [4.7, 15.34]
  2 studies · 1200 participants
  High

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Minoxidil vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found